Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Iodine I 131 Tositumomab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Iodine I 131 Tositumomab | DRUG | - |
Inclusion Criteria: * At least 18 years of age * Histologically confirmed diagnosis of follicular lymphoma, Grade 1, 2, or 3, or diffuse large cell lymphoma (WHO/REAL classification). Follicular, small cleaved; Follicular, mixed small cleaved and large cell; Follicular large cell lymphoma Transfor...
Iodine I 131 Tositumomab is used for Non-Hodgkin's Lymphoma, specifically studied in untreated or transformed follicular Non-Hodgkin's Lymphoma. It is an investigational small molecule in Phase 1 clinical development, and it is not approved by the FDA.
Iodine I 131 Tositumomab is being developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical research on this investigational drug for Non-Hodgkin's Lymphoma.
Iodine I 131 Tositumomab is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still being studied for safety and efficacy in patients with Non-Hodgkin's Lymphoma.
Iodine I 131 Tositumomab has one completed clinical trial, NCT00062894, which studied untreated or transformed follicular Non-Hodgkin's Lymphoma. The trial enrolled 12 participants in the United States and was not randomized or double-blinded.
Iodine I 131 Tositumomab is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Non-Hodgkin's Lymphoma, and its safety and effectiveness have not been established.